AbbVie Buys Apogee for $10.9 Billion to Deepen Immunology Pipeline

Q: By doubling down on immunology, is AbbVie strategically ignoring the multi-billion dollar obesity drug market?

No. AbbVie is prioritizing immunology because it is where it already has scale, commercial strength and near-term visibility, not because it is abandoning obesity. The Apogee deal fits a clear post-Humira strategy: deepen AbbVie’s leadership in inflammatory disease with assets that can plug into its existing immunology franchise. Apogee’s lead programs in atopic dermatitis and asthma are clinically aligned with AbbVie’s strengths, and AbbVie expects the acquisition to add to adjusted earnings starting in 2032. With Skyrizi and Rinvoq already driving strong growth, this is a logical use of capital to reinforce a proven business. At the same time, AbbVie is not absent from obesity. It has reported positive Phase 1 data for ABBV-295, a long-acting amylin analog, and has described obesity as an emerging growth area. The company is also building obesity R&D capabilities and pursuing a differentiated non-GLP-1 approach rather than trying to enter the market head-on with a late me-too incretin drug. What is true is that AbbVie is behind the leaders in obesity. Eli Lilly and Novo Nordisk have a major head start, and AbbVie’s obesity effort remains early-stage, while its immunology investments are larger, more mature and closer to commercial payoff. So the strategic picture is not that AbbVie is ignoring obesity; it is sequencing its bets. It is doubling down where it has competitive advantage now, while making a smaller, earlier wager on obesity for longer-term diversification.

3 articles · Updated · AbbVie · Jun 22

$135.11 per share in cash will give AbbVie all outstanding Apogee shares under a definitive agreement unanimously approved by both boards.
AbbVie said the deal expands its immunology franchise and speeds its push into respiratory disease by adding Apogee's clinical-stage pipeline in atopic dermatitis and asthma.
Zumilokibart, Apogee's lead IL-13 antibody, posted Phase 2 atopic dermatitis results with about two-thirds of treated patients achieving significant skin clearance at 16 weeks.
The transaction is expected to close in the third quarter of 2026, pending Apogee shareholder and regulatory approval, and AbbVie expects it to add to adjusted diluted EPS starting in 2032.

Sources

AbbVie17h ago

AbbVie to Acquire Apogee Therapeutics for $10.9 Billion, Deepening Immunology Portfolio

Finimize17h ago

AbbVie Nears $10.9 Billion Deal For Apogee Therapeutics - Finimize

Yahoo Finance17h ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

10 Sources

Is AbbVie's $10.9B deal a smart buy or just another symptom of the industry's 'patent cliff' panic?

By doubling down on immunology, is AbbVie strategically ignoring the multi-billion dollar obesity drug market?

AbbVie’s $10.9 Billion Acquisition of Apogee Therapeutics: Strategic Pipeline Expansion and the Race for Next-Gen Immunology Blockbusters

Overview

AbbVie announced on June 18, 2026, that it will acquire Apogee Therapeutics for $10.9 billion, aiming to strengthen its position and secure future growth in the immunology sector. The deal involves merging Andor Merger Co., a subsidiary of AbbVie, into Apogee, which will then operate as a wholly owned subsidiary. News of the acquisition quickly boosted Apogee’s share price by nearly 53% in pre-market trading. This strategic move highlights AbbVie’s commitment to expanding its immunology pipeline and maintaining leadership in a highly competitive market.

...